中文名：葡美替尼（SCC244）
英文名：Glumetinib (SCC244)
純度：Moligand?，≥98%
貨號：G414110
Cas號：1642581-63-2
存儲溫度：-20°C儲存
運輸條件：超低溫運輸
產(chǎn)品介紹：
Information
Glumetinib (SCC244) Glumetinib (SCC244) is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.
Targets
c-Met (Cell-free assay) 0.42 nM
In vitro
SCC244 strongly inhibits c-Met phosphorylation as well as AKT and ERK phosphorylation in EBC-1, MKN-45 cells harboring an amplified MET gene and U87MG cells responsive to HGF stimulation. SCC244 elicits selective and profound effects against c-Met-driven cancer cell proliferation. It inhibits c-Met-dependent neoplastic phenotypes of metastasis and angiogenesis.
In vivo
In xenografts of human tumor cell lines or non-small cell lung cancer and hepatocellular carcinoma patient-derived tumor tissue driven by MET aberration, SCC244 administration exhibits robust antitumor activity at the well-tolerated doses. In addition, the in vivo antitumor activity of SCC244 involves the inhibition of c-Met downstream signaling via a mechanism of combined antiproliferation and antiangiogenic effects.
Cell Research(from reference)
Cell lines：U87MG cells?
Concentrations：5, 10, 20 nM?
Incubation Time：2 h?
查看阿拉丁官網(wǎng)此產(chǎn)品相關對應頁面：https://www.aladdin-e.com/zh_cn/G414110.html
關鍵字： 谷美替尼;UNII-7JTT036WGX ; SCC244 ; SC-C244
上海阿拉丁生化科技股份有限公司是A股上市公司（（股票代碼：688179），專注于科研試劑的研發(fā)、生產(chǎn)和銷售，已陸續(xù)建立多個工廠和研發(fā)中心。作為領軍企業(yè)，阿拉丁始終堅持質(zhì)量第一，連續(xù)13年被評為“最受歡迎試劑品牌”。
阿拉丁目前常備庫存試劑產(chǎn)品品種超過7萬種，SKU總數(shù)超過46萬，產(chǎn)品線涵蓋了化學試劑、生化試劑、藥靶配體、蛋白質(zhì)和抗體等多個領域，是國內(nèi)少數(shù)化學試劑到生物試劑全面發(fā)展的國產(chǎn)試劑品牌，產(chǎn)品同步發(fā)布在我們國內(nèi)外電商平臺。